It's finally happening, the inevitable pivot to reach/frequency for a buy and bill product.
Good idea? Hell no.
Tragic mistake? Just another in a long-line.
Senior management thinking they can get out of the corner they painted themselves into by pushing field sales in a completely inappropriate direction? Absolutely.
You could try to explain to them that R/F doesn't even work for Entresto, let alone account-selling/buy and bill, but they wouldn't even begin to understand.
It's big pharma's hail-mary: once senior management and marketing have completely burnt it to the ground, tell field sales to go out and make twice as many calls, as though that will fix everything.
It would be worth a laugh if we didn't know what comes next.
That's right, this is the last step before layoffs (most of you have seen this before).
Take it seriously and use this time to protect yourself and your families. It's coming.
Good idea? Hell no.
Tragic mistake? Just another in a long-line.
Senior management thinking they can get out of the corner they painted themselves into by pushing field sales in a completely inappropriate direction? Absolutely.
You could try to explain to them that R/F doesn't even work for Entresto, let alone account-selling/buy and bill, but they wouldn't even begin to understand.
It's big pharma's hail-mary: once senior management and marketing have completely burnt it to the ground, tell field sales to go out and make twice as many calls, as though that will fix everything.
It would be worth a laugh if we didn't know what comes next.
That's right, this is the last step before layoffs (most of you have seen this before).
Take it seriously and use this time to protect yourself and your families. It's coming.